{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:55:01Z","timestamp":1790848501213,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Recently, aprepitant has been recommended in carboplatin-based regimens, but there are limited reports on the efficacy of administering aprepitant, palonosetron, and dexamethasone (DEX) in carboplatin-containing regimens. Moreover, because aprepitant is an expensive drug, confirming its effectiveness is very important from the medical cost perspective. In this study, we examined the efficacy of prophylactically administered aprepitant, palonosetron and DEX, in paclitaxel and carboplatin (TC) combination chemotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with gynecologic cancer who were treated with paclitaxel (175\u2009mg\/m<jats:sup>2<\/jats:sup>) and carboplatin (area under the curve, AUC\u2009=\u20095\u20136) combination chemotherapy were retrospectively evaluated. The complete response (CR) rate, severity of nausea, and incidence of anorexia in the first course were compared between patients who did not receive aprepitant (control group) and those who received (aprepitant group).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The 106 patients were divided into two groups, consisting of 52 and 54 the control and aprepitant groups, respectively, and the patient background showed no significant difference between both groups. The CR rate of the overall phase between the control and aprepitant groups was 73.1 vs. 74.1%, that in the acute phase was 98.1 vs. 100%, and in the delayed phase was 75.0 vs. 74.1%, respectively, without any significant difference. The severity of nausea and incidence of anorexia were also not significantly different between both groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The results of the study suggest that adding aprepitant to palonosetron and DEX does not prevent carboplatin-induced nausea and vomiting in gynecologic cancer patients. Therefore, adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40780-021-00204-z","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T23:11:10Z","timestamp":1622502670000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer"],"prefix":"10.1186","volume":"7","author":[{"given":"Yuko","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Mitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoh","family":"Takekuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5350-2950","authenticated-orcid":false,"given":"Mitsuru","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"key":"204_CR1","doi-asserted-by":"publisher","unstructured":"Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol. 2015;33(19):2129\u201335. https:\/\/doi.org\/10.1200\/JCO.2014.58.4391.","DOI":"10.1200\/JCO.2014.58.4391"},{"issue":"1","key":"204_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ygyno.2014.01.042","volume":"133","author":"D Lorusso","year":"2014","unstructured":"Lorusso D, Petrelli F, Coinu A, Raspagliesi F, Barni S. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecol Oncol. 2014;133(1):117\u201323. https:\/\/doi.org\/10.1016\/j.ygyno.2014.01.042.","journal-title":"Gynecol Oncol"},{"issue":"17","key":"204_CR3","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/jnci\/djg036","volume":"95","author":"A du Bois","year":"2003","unstructured":"du Bois A, L\u00fcck HJ, Meier W, Adams HP, M\u00f6bus V, Costa S, et al. A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95(17):1320\u20139. https:\/\/doi.org\/10.1093\/jnci\/djg036.","journal-title":"J Natl Cancer Inst"},{"key":"204_CR4","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ygyno.2009.02.008","volume":"133","author":"S Mabuchi","year":"2009","unstructured":"Mabuchi S, Morishige K, Fujita M, Tsutsui T, Sakata M, Enomoto T, et al. The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy. Gynecol Oncol. 2009;133:200\u20134.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"204_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3802\/jgo.2015.26.4.311","volume":"26","author":"S Fujiwara","year":"2015","unstructured":"Fujiwara S, Terai Y, Tsunetoh S, Sasaki H, Kanemura M, Ohmichi M. Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer. J Gynecol Oncol. 2015;26(4):311\u20139. https:\/\/doi.org\/10.3802\/jgo.2015.26.4.311.","journal-title":"J Gynecol Oncol"},{"key":"204_CR6","doi-asserted-by":"publisher","unstructured":"Yoshida N, Taguchi T, Nakanishi M, Inoue K, Okayama T, Ishikawa T, et al. Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens. BMC Pharmacol Toxicol. 2019;20(1):6. https:\/\/doi.org\/10.1186\/s40360-018-0278-2.","DOI":"10.1186\/s40360-018-0278-2"},{"key":"204_CR7","doi-asserted-by":"publisher","unstructured":"Karayama M, Inui N, Tanaka K, Yasui H, Hozumi H, Suzuki Y, et al. Prophylactic aprepitant is better than salvage for carboplatin-based chemotherapy: a propensity score-matched analysis. Med Oncol. 2018;35(11):139. https:\/\/doi.org\/10.1007\/s12032-018-1199-z.","DOI":"10.1007\/s12032-018-1199-z"},{"issue":"Supplement 5","key":"204_CR8","doi-asserted-by":"publisher","first-page":"v232","DOI":"10.1093\/annonc\/mdq194","volume":"21","author":"F Roila","year":"2010","unstructured":"Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference. Ann Oncol. 2010;21(Supplement 5):v232\u201343.","journal-title":"Ann Oncol"},{"key":"204_CR9","doi-asserted-by":"publisher","unstructured":"Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29(31):4189\u201398. https:\/\/doi.org\/10.1200\/JCO.2010.34.4614.","DOI":"10.1200\/JCO.2010.34.4614"},{"key":"204_CR10","doi-asserted-by":"publisher","unstructured":"Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27(suppl 5):v119\u201333. https:\/\/doi.org\/10.1093\/annonc\/mdw270.","DOI":"10.1093\/annonc\/mdw270"},{"key":"204_CR11","doi-asserted-by":"publisher","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35(28):3240\u201361. https:\/\/doi.org\/10.1200\/JCO.2017.74.4789.","DOI":"10.1200\/JCO.2017.74.4789"},{"key":"204_CR12","doi-asserted-by":"publisher","first-page":"883","DOI":"10.6004\/jnccn.2017.0117","volume":"15","author":"MJ Berger","year":"2017","unstructured":"Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, et al. NCCN Guidelines Insights: Antiemesis, Version 2.2017. J Natl Compr Cancer Netw. 2017;15:883\u201393.","journal-title":"J Natl Compr Cancer Netw"},{"key":"204_CR13","doi-asserted-by":"crossref","unstructured":"Aogi K, Takeuchi H, Saeki T, Aiba K, Tamura K, Iino K, et al. Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for antiemesis. Int J Clin Oncol. 2021;26(1):1\u201317.","DOI":"10.1007\/s10147-020-01818-3"},{"issue":"2","key":"204_CR14","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/IGC.0000000000000593","volume":"26","author":"JP Micha","year":"2016","unstructured":"Micha JP, Rettenmaier MA, Brown JV, Mendivil A, Abaid LN, Lopez KL, et al. A Randomized Controlled Pilot Study Comparing the Impact of Aprepitant and Fosaprepitant on Chemotherapy Induced Nausea and Vomiting in Patients Treated for Gynecologic Cancer. Int J Gynecol Cancer. 2016;26(2):389\u201393. https:\/\/doi.org\/10.1097\/IGC.0000000000000593.","journal-title":"Int J Gynecol Cancer"},{"key":"204_CR15","doi-asserted-by":"publisher","unstructured":"Yokoe T, Hayashida T, Nagayama A, Nakashoji A, Maeda H, Seki T, et al. Effectiveness of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: a systematic review and network meta-analysis. Oncologist. 2019;24(6):e347\u201357. https:\/\/doi.org\/10.1634\/theoncologist.2018-0140.","DOI":"10.1634\/theoncologist.2018-0140"},{"key":"204_CR16","unstructured":"Maehara M, Ueda T, Miyahara D, Takahashi Y, Miyata K, Nam SO, et al. Clinical efficacy of aprepitant in patients with gynecological cancer after chemotherapy using paclitaxel and carboplatin. Anticancer Res. 2015;35(8):4527\u201334."},{"issue":"9","key":"204_CR17","doi-asserted-by":"publisher","first-page":"657","DOI":"10.2217\/cer-2018-0104","volume":"8","author":"LS Schwartzberg","year":"2019","unstructured":"Schwartzberg LS, Marks SM, Gabrail NY, Geller RB, Kish J. Real-world effectiveness of palonosetron-based antiemetic regimens: preventing chemotherapy-induced nausea and vomiting. J Comp Eff Res. 2019;8(9):657\u201370. https:\/\/doi.org\/10.2217\/cer-2018-0104.","journal-title":"J Comp Eff Res"},{"key":"204_CR18","doi-asserted-by":"publisher","unstructured":"Yahata H, Kobayashi H, Sonoda K, Shimokawa M, Ohgami T, Saito T, et al. Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol. 2016;21(3):491\u20137. https:\/\/doi.org\/10.1007\/s10147-015-0928-y.","DOI":"10.1007\/s10147-015-0928-y"},{"key":"204_CR19","first-page":"105","volume":"7","author":"M Takeuchi","year":"2014","unstructured":"Takeuchi M, Goto A, Tsubai T, Hida H, Mukoyama N, Otsuka M. The effectiveness of aprepitant for gastrointestinal symptoms induced by highly and moderately emetogenic platinum-containing drugs. Jpn J Pharm Palliat Care Sci. 2014;7:105\u201310.","journal-title":"Jpn J Pharm Palliat Care Sci"},{"key":"204_CR20","doi-asserted-by":"publisher","unstructured":"Iihara H, Ishihara M, Fujii H, Yoshimi C, Yamada M, Suzuki A, et al. Comparison of the control of nausea and vomiting among several moderately emetic-risk chemotherapy regimens. J Cancer. 2016;7(5):569\u201375. https:\/\/doi.org\/10.7150\/jca.13637.","DOI":"10.7150\/jca.13637"},{"key":"204_CR21","doi-asserted-by":"publisher","unstructured":"Kusagaya H, Inui N, Karayama M, Fujisawa T, Enomoto N, Kuroishi S, et al. Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer. Lung Cancer. 2015;90(3):410\u20136. https:\/\/doi.org\/10.1016\/j.lungcan.2015.11.009.","DOI":"10.1016\/j.lungcan.2015.11.009"},{"key":"204_CR22","doi-asserted-by":"publisher","unstructured":"Suzuki K, Yamanaka T, Hashimoto H, Shimada Y, Arata K, Matsui R, et al. Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. Ann Oncol. 2016;27(8):1601\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdw220.","DOI":"10.1093\/annonc\/mdw220"},{"issue":"6","key":"204_CR23","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s00520-014-2175-6","volume":"22","author":"M Popovic","year":"2014","unstructured":"Popovic M, Warr DG, Deangelis C, Tsao M, Chan KK, Poon M, et al. Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer. 2014;22(6):1685\u201397. https:\/\/doi.org\/10.1007\/s00520-014-2175-6.","journal-title":"Support Care Cancer"},{"key":"204_CR24","doi-asserted-by":"publisher","unstructured":"Tsukiyama I, Hasegawa S, Ikeda Y, Takeuchi M, Tsukiyama S, Kurose Y, et al. Cost-effectiveness of aprepitant in Japanese patients treated with cisplatin-containing highly emetogenic chemotherapy. Cancer Sci. 2018;109(9):2881\u20138. https:\/\/doi.org\/10.1111\/cas.13736.","DOI":"10.1111\/cas.13736"},{"key":"204_CR25","first-page":"15","volume":"70","author":"T Abe","year":"2012","unstructured":"Abe T, Yokoyama T, Kurokawa Y, Hayabe H, Miyasato A, Osato Y, et al. Proper use of antiemetic drugs in an outpatient chemotherapy center. J Tokyo Med Univ. 2012;70:15\u201325.","journal-title":"J Tokyo Med Univ"},{"key":"204_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40780-018-0128-9","volume":"4","author":"H Shimizu","year":"2018","unstructured":"Shimizu H, Suzuki K, Uchikura T, Tsuji D, Yamanaka T, Hashimoto H, et al. Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial). J Pharm Health Care Sci. 2018;4:31. https:\/\/doi.org\/10.1186\/s40780-018-0128-9.","journal-title":"J Pharm Health Care Sci"},{"key":"204_CR27","doi-asserted-by":"publisher","unstructured":"Sakamoto T, Saito Y, Kobayashi M, Yamada T, Takekuma Y, Nakai M, et al. Effect of palonosetron and dexamethasone administration on the prevention of gastrointestinal symptoms in hepatic arterial chemoembolization with epirubicin. Support Care Cancer. 2020;28(7):3251\u20137. https:\/\/doi.org\/10.1007\/s00520-019-05178-1.","DOI":"10.1007\/s00520-019-05178-1"},{"issue":"3","key":"204_CR28","first-page":"109","volume":"76","author":"R Schoffelen","year":"2018","unstructured":"Schoffelen R, Lankheet AG, van Herpen CML, van der Hoeven JJM, Desar IME, Kramers C. Drug\u2013drug interactions with aprepitant in antiemetic prophylaxis for chemotherapy. Neth J Med. 2018;76(3):109\u201314.","journal-title":"Neth J Med"},{"key":"204_CR29","doi-asserted-by":"publisher","unstructured":"McCrea JB, Majumdar AK, Goldberg MR, Iwamoto M, Gargano C, Panebianco DL, et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther. 2003;74(1):17\u201324. https:\/\/doi.org\/10.1016\/S0009-9236(03)00066-3.","DOI":"10.1016\/S0009-9236(03)00066-3"},{"issue":"5-6","key":"204_CR30","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00228-005-0907-8","volume":"61","author":"M Depr\u00e9","year":"2005","unstructured":"Depr\u00e9 M, Van Hecken A, Oeyen M, De Lepeleire I, Laethem T, Rothenberg P, et al. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol. 2005;61(5-6):341\u20136. https:\/\/doi.org\/10.1007\/s00228-005-0907-8.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"204_CR31","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s00520-013-2106-y","volume":"22","author":"JD Lundberg","year":"2014","unstructured":"Lundberg JD, Crawford BS, Phillips G, Berger MJ, Wesolowski R. Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant. Support Care Cancer. 2014;22(6):1461\u20136. https:\/\/doi.org\/10.1007\/s00520-013-2106-y.","journal-title":"Support Care Cancer"},{"issue":"9","key":"204_CR32","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1111\/jog.13378","volume":"43","author":"Y Sugimori","year":"2017","unstructured":"Sugimori Y, Ota T, Ujihira T, Ishiguro T, Ogishima D. A phase II randomized study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer. J Obstet Gynaecol Res. 2017;43(9):1454\u20139. https:\/\/doi.org\/10.1111\/jog.13378.","journal-title":"J Obstet Gynaecol Res"},{"key":"204_CR33","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/cas.12675","volume":"106","author":"Y Komatsu","year":"2018","unstructured":"Komatsu Y, Okita K, Yuki S, Furuhata T, Fukushima H, Masuko H, et al. Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron. Cancer Sci. 2018;106:891\u20135.","journal-title":"Cancer Sci"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-021-00204-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-021-00204-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-021-00204-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T23:34:20Z","timestamp":1622504060000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-021-00204-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["204"],"URL":"https:\/\/doi.org\/10.1186\/s40780-021-00204-z","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,1]]},"assertion":[{"value":"28 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Institutional Review Board of the Hokkaido University Hospital (approved number: 018\u20130390). All the procedures performed in studies involving human participants were out in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest associated with this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}